232 related articles for article (PubMed ID: 29232121)
21. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
[TBL] [Abstract][Full Text] [Related]
22. Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors.
Sivakumaren SC; Shim H; Zhang T; Ferguson FM; Lundquist MR; Browne CM; Seo HS; Paddock MN; Manz TD; Jiang B; Hao MF; Krishnan P; Wang DG; Yang TJ; Kwiatkowski NP; Ficarro SB; Cunningham JM; Marto JA; Dhe-Paganon S; Cantley LC; Gray NS
Cell Chem Biol; 2020 May; 27(5):525-537.e6. PubMed ID: 32130941
[TBL] [Abstract][Full Text] [Related]
23. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.
Rao S; Gurbani D; Du G; Everley RA; Browne CM; Chaikuad A; Tan L; Schröder M; Gondi S; Ficarro SB; Sim T; Kim ND; Berberich MJ; Knapp S; Marto JA; Westover KD; Sorger PK; Gray NS
Cell Chem Biol; 2019 Jun; 26(6):818-829.e9. PubMed ID: 30982749
[TBL] [Abstract][Full Text] [Related]
24. Mechanistic Investigation of Lysine-Targeted Covalent Inhibition of PI3Kδ via ONIOM QM:QM Computations.
Fındık V; Varınca Gerçik BT; Sinek Ö; Erdem SS; Ruiz-López MF
J Chem Inf Model; 2022 Dec; 62(24):6775-6787. PubMed ID: 35980989
[TBL] [Abstract][Full Text] [Related]
25. Discovery of highly potent, selective, covalent inhibitors of JAK3.
Kempson J; Ovalle D; Guo J; Wrobleski ST; Lin S; Spergel SH; Duan JJ; Jiang B; Lu Z; Das J; Yang BV; Hynes J; Wu H; Tokarski J; Sack JS; Khan J; Schieven G; Blatt Y; Chaudhry C; Salter-Cid LM; Fura A; Barrish JC; Carter PH; Pitts WJ
Bioorg Med Chem Lett; 2017 Oct; 27(20):4622-4625. PubMed ID: 28927786
[TBL] [Abstract][Full Text] [Related]
26. Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.
Zhao Z; Liu Q; Bliven S; Xie L; Bourne PE
J Med Chem; 2017 Apr; 60(7):2879-2889. PubMed ID: 28326775
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies.
Liu X; Wang A; Liang X; Liu J; Zou F; Chen C; Zhao Z; Deng Y; Wu H; Qi Z; Wang B; Wang L; Liu F; Xu Y; Wang W; Fernandes SM; Stone RM; Galinsky IA; Brown JR; Loh T; Griffin JD; Zhang S; Weisberg EL; Zhang X; Liu J; Liu Q
Oncotarget; 2016 Aug; 7(33):53515-53525. PubMed ID: 27447747
[TBL] [Abstract][Full Text] [Related]
28. Piperidinyl-embeded chalcones possessing anti PI3Kδ inhibitory properties exhibit anti-atopic properties in preclinical models.
Dumontet C; Beck G; Gardebien F; Haudecoeur R; Mathé D; Matera EL; Tourette A; Mattei E; Esmenjaud J; Boyère C; Nurisso A; Peuchmaur M; Pérès B; Bouchaud G; Magnan A; Monneret G; Boumendjel A
Eur J Med Chem; 2018 Oct; 158():405-413. PubMed ID: 30237123
[TBL] [Abstract][Full Text] [Related]
29. Cell-active, irreversible covalent inhibitors that selectively target the catalytic lysine of EGFR by using fluorosulfate-based SuFEx chemistry.
Tang G; Wang W; Wang X; Ding K; Ngan SC; Chen JY; Sze SK; Gao L; Yuan P; Lu X; Yao SQ
Eur J Med Chem; 2023 Nov; 259():115671. PubMed ID: 37499291
[TBL] [Abstract][Full Text] [Related]
30. Irreversible protein kinase inhibitors.
Garuti L; Roberti M; Bottegoni G
Curr Med Chem; 2011; 18(20):2981-94. PubMed ID: 21651479
[TBL] [Abstract][Full Text] [Related]
31. The Cysteinome of Protein Kinases as a Target in Drug Development.
Chaikuad A; Koch P; Laufer SA; Knapp S
Angew Chem Int Ed Engl; 2018 Apr; 57(16):4372-4385. PubMed ID: 28994500
[TBL] [Abstract][Full Text] [Related]
32. Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation.
Zhang T; Hatcher JM; Teng M; Gray NS; Kostic M
Cell Chem Biol; 2019 Nov; 26(11):1486-1500. PubMed ID: 31631011
[TBL] [Abstract][Full Text] [Related]
33. Selective and potent small-molecule inhibitors of PI3Ks.
Jeong Y; Kwon D; Hong S
Future Med Chem; 2014 May; 6(7):737-56. PubMed ID: 24941870
[TBL] [Abstract][Full Text] [Related]
34. Discovery of novel pyrrolidineoxy-substituted heteroaromatics as potent and selective PI3K delta inhibitors with improved physicochemical properties.
Hoegenauer K; Soldermann N; Hebach C; Hollingworth GJ; Lewis I; von Matt A; Smith AB; Wolf RM; Wilcken R; Haasen D; Burkhart C; Zécri F
Bioorg Med Chem Lett; 2016 Dec; 26(23):5657-5662. PubMed ID: 27816514
[TBL] [Abstract][Full Text] [Related]
35. Development of single and mixed isoform selectivity PI3Kδ inhibitors by targeting Asn836 of PI3Kδ.
Miller MS; Mountford SJ; Pinson JA; Zheng Z; Künzli M; Patel V; Hogg SJ; Shortt J; Jennings IG; Thompson PE
Bioorg Med Chem Lett; 2016 Oct; 26(19):4790-4794. PubMed ID: 27561716
[TBL] [Abstract][Full Text] [Related]
36. Identification of new dual spleen tyrosine kinase (Syk) and phosphoionositide-3-kinase δ (PI3Kδ) inhibitors using ligand and structure-based integrated ideal pharmacophore models.
Kaur M; Silakari O
SAR QSAR Environ Res; 2016 Jun; 27(6):469-99. PubMed ID: 27431536
[TBL] [Abstract][Full Text] [Related]
37. Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure.
Jia W; Luo S; Zhao W; Xu W; Zhong Y; Kong D
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234743
[TBL] [Abstract][Full Text] [Related]
38. Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases.
Zhu Y; Hu X
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296718
[TBL] [Abstract][Full Text] [Related]
39. Identification and optimisation of a 4',5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors.
Fairhurst RA; Imbach-Weese P; Gerspacher M; Caravatti G; Furet P; Zoller T; Fritsch C; Haasen D; Trappe J; Guthy DA; Arz D; Wirth J
Bioorg Med Chem Lett; 2015 Sep; 25(17):3569-74. PubMed ID: 26206504
[TBL] [Abstract][Full Text] [Related]
40. Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances.
Liu X; Wang A; Liang X; Chen C; Liu J; Zhao Z; Wu H; Deng Y; Wang L; Wang B; Wu J; Liu F; Fernandes SM; Adamia S; Stone RM; Galinsky IA; Brown JR; Griffin JD; Zhang S; Loh T; Zhang X; Wang W; Weisberg EL; Liu J; Liu Q
Oncotarget; 2016 May; 7(22):32641-51. PubMed ID: 27081697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
